These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38844967)

  • 1. Resistin predicts disease severity and survival in patients with pulmonary arterial hypertension.
    Gao L; Skinner J; Nath T; Lin Q; Griffiths M; Damico RL; Pauciulo MW; Nichols WC; Hassoun PM; Everett AD; Johns RA
    Respir Res; 2024 Jun; 25(1):235. PubMed ID: 38844967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension.
    Simpson CE; Damico RL; Hassoun PM; Martin LJ; Yang J; Nies MK; Vaidya RD; Brandal S; Pauciulo MW; Austin ED; Ivy DD; Nichols WC; Everett AD
    Chest; 2020 Jun; 157(6):1606-1616. PubMed ID: 31987881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypochloremia Is a Noninvasive Predictor of Mortality in Pulmonary Arterial Hypertension.
    Prins KW; Kalra R; Rose L; Assad TR; Archer SL; Bajaj NS; Weir EK; Prisco SZ; Pritzker M; Lutsey PL; Brittain EL; Thenappan T
    J Am Heart Assoc; 2020 Mar; 9(5):e015221. PubMed ID: 32079477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival.
    Yang J; Griffiths M; Nies MK; Brandal S; Damico R; Vaidya D; Tao X; Simpson CE; Kolb TM; Mathai SC; Pauciulo MW; Nichols WC; Ivy DD; Austin ED; Hassoun PM; Everett AD
    BMC Med; 2020 Oct; 18(1):268. PubMed ID: 33019943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.
    Damico R; Kolb TM; Valera L; Wang L; Housten T; Tedford RJ; Kass DA; Rafaels N; Gao L; Barnes KC; Benza RL; Rand JL; Hamid R; Loyd JE; Robbins IM; Hemnes AR; Chung WK; Austin ED; Drummond MB; Mathai SC; Hassoun PM
    Am J Respir Crit Care Med; 2015 Jan; 191(2):208-18. PubMed ID: 25489667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
    Mullin CJ; Khair RM; Damico RL; Kolb TM; Hummers LK; Hassoun PM; Steen VD; Mathai SC;
    Arthritis Rheumatol; 2019 Oct; 71(10):1691-1700. PubMed ID: 31066998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency.
    Sweatt AJ; Miyagawa K; Rhodes CJ; Taylor S; Del Rosario PA; Hsi A; Haddad F; Spiekerkoetter E; Bental-Roof M; Bland RD; Swietlik EM; Gräf S; Wilkins MR; Morrell NW; Nicolls MR; Rabinovitch M; Zamanian RT
    Chest; 2021 Oct; 160(4):1442-1458. PubMed ID: 34181952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension.
    Calvier L; Legchenko E; Grimm L; Sallmon H; Hatch A; Plouffe BD; Schroeder C; Bauersachs J; Murthy SK; Hansmann G
    Heart; 2016 Mar; 102(5):390-6. PubMed ID: 26869635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension.
    Argula RG; Karwa A; Lauer A; Gregg D; Silver RM; Feghali-Bostwick C; Schanpp LM; Egbert K; Usher BW; Ramakrishnan V; Hassoun PM; Strange C
    Ann Am Thorac Soc; 2017 May; 14(5):682-689. PubMed ID: 28282243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum uric acid is associated with disease severity and may predict clinical outcome in patients of pulmonary arterial hypertension secondary to connective tissue disease in Chinese: a single-center retrospective study.
    Wang J; Wang Y; Li X; Huang Y; Sun X; Wang Q; Zhang M
    BMC Pulm Med; 2020 Oct; 20(1):272. PubMed ID: 33076877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening.
    Griffiths M; Yang J; Simpson CE; Vaidya D; Nies M; Brandal S; Damico R; Ivy DD; Austin ED; Pauciulo MW; Lutz KA; Rosenzweig EB; Hirsch R; Yung D; Nichols WC; Everett AD
    Chest; 2021 Jul; 160(1):297-306. PubMed ID: 33609516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes.
    Ramjug S; Hussain N; Hurdman J; Billings C; Charalampopoulos A; Elliot CA; Kiely DG; Sabroe I; Rajaram S; Swift AJ; Condliffe R
    Chest; 2017 Jul; 152(1):92-102. PubMed ID: 28223154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival in rheumatoid arthritis-associated pulmonary arterial hypertension compared with idiopathic pulmonary arterial hypertension.
    Sadeghi S; Granton JT; Akhavan P; Pasarikovski CR; Roos AM; Thenganatt J; Moric J; Johnson SR
    Respirology; 2015 Apr; 20(3):481-7. PubMed ID: 25583377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension.
    Douwes JM; Roofthooft MT; Bartelds B; Talsma MD; Hillege HL; Berger RM
    Int J Cardiol; 2013 Sep; 168(2):1370-7. PubMed ID: 23340486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Lymphangiogenic Factors With Pulmonary Arterial Hypertension in Systemic Sclerosis.
    Didriksen H; Molberg Ø; Fretheim H; Gude E; Jordan S; Brunborg C; Palchevskiy V; Garen T; Midtvedt Ø; Andreassen AK; Distler O; Belperio J; Hoffmann-Vold AM
    Arthritis Rheumatol; 2021 Jul; 73(7):1277-1287. PubMed ID: 33497027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatoma-derived Growth Factor Predicts Disease Severity and Survival in Pulmonary Arterial Hypertension.
    Yang J; Nies MK; Fu Z; Damico R; Korley FK; Hassoun PM; Ivy DD; Austin ED; Everett AD
    Am J Respir Crit Care Med; 2016 Nov; 194(10):1264-1272. PubMed ID: 27254543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Significance of Proteomics-Discovered Circulating Inflammatory Biomarkers in Patients With Pulmonary Arterial Hypertension.
    Yokokawa T; Boucherat O; Martineau S; Lemay SE; Breuils-Bonnet S; Krishna V; Kalyana-Sundaram S; Jeyaseelan J; Potus F; Bonnet S; Provencher S
    J Am Heart Assoc; 2024 Jun; 13(12):e032888. PubMed ID: 38874078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).
    Preston IR; Roberts KE; Miller DP; Sen GP; Selej M; Benton WW; Hill NS; Farber HW
    Circulation; 2015 Dec; 132(25):2403-11. PubMed ID: 26510696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension.
    Filusch A; Zelniker T; Baumgärtner C; Eschricht S; Frey N; Katus HA; Chorianopoulos E
    Clin Res Cardiol; 2011 Oct; 100(10):879-85. PubMed ID: 21479966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric pulmonary hypertension: insulin-like growth factor-binding protein 2 is a novel marker associated with disease severity and survival.
    Griffiths M; Yang J; Nies M; Vaidya D; Brandal S; Williams M; Matsui EC; Grant T; Damico R; Ivy D; Austin ED; Nichols WC; Pauciulo MW; Lutz K; Rosenzweig EB; Hirsch R; Yung D; Everett AD
    Pediatr Res; 2020 Dec; 88(6):850-856. PubMed ID: 32927467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.